A Randomized, Double-Blind, Controlled (Positive and Placebo) Phase II Clinical Trial to Estimate Safty and Immunogenicity of the SCT1000 in Healthy Women Aged 18 to 45 Years
Latest Information Update: 08 Sep 2023
At a glance
- Drugs SCT 1000 (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
- Indications Human papillomavirus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sinocelltech
- 21 Oct 2021 Status changed from not yet recruiting to recruiting.
- 30 Sep 2021 New trial record